Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

NCT01927705 is registered in ClinicalTrials.gov with Kang Stem Biotech Co., Ltd. as lead sponsor.

NCT NCT01927705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01927705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
Lead sponsor
Kang Stem Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2013
Completion date
May 31, 2015
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis